Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'
Executive Summary
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.
You may also be interested in...
Beyond Viatris: Kiran Mazumdar-Shaw Talks Next Steps For Biocon Biologics
As Biocon Biologics completes its integration of the biosimilars front-end business that it acquired from former partner Viatris, Biocon founder and chairperson Kiran Mazumdar-Shaw talks to Generics Bulletin about how the firm is now capturing the full value of its biosimilars, while also looking at expanding into new markets previously unserved by Viatris.
Price Negotiation Purgatory: Upcoming Biosimilars Couldn’t Keep Stelara, NovoLog Off The List
Neither product counts as an ‘extended monopoly’ drug under the Inflation Reduction Act, meaning biosimilar entry cannot prevent Medicare from negotiating its price.
New Insulin Manufacturer For Civica
Ypsomed AG will manufacture insulin dosing injector pens for non-profit Civica. Civica has also paired up with AmerisourceBergen for generics supply chain support across the US.